Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Pharma Ups Stake in Shanghai Sunway

publication date: Jun 25, 2013
Shanghai Pharmaceuticals purchased another 11% of Shanghai Sunway Biotech, bringing its total holdings in the company to 81%. In 2005, Sunway was granted CFDA approval of a gene therapy treatment, using an oncolytic adenovirus as a delivery vehicle, for late-stage refractory nasopharyngeal cancer. Shanghai Pharma paid 1 million RMB ($160,000) for its purchase of the 11% stake. More details....

Stock Symbols: (SHA: 601607)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital